Lefkothea Antonara

Dr. Lefkothea Antonara


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2025 in Nanomaterials
Verified
Journal Article
Open access
PDF file
LALefkothea Antonara
Lefkothea Antonara
ETEfstathia Triantafyllopoulou
Efstathia Triantafyllopoulou
MCMaria Chountoulesi
Maria Chountoulesi
Natassa PippaNatassa Pippa
Natassa Pippa
PDParaskevas P Dallas
Paraskevas P Dallas
DRDimitrios Rekkas
Dimitrios Rekkas
Lipid-based nanocarriers are ideal drug delivery systems for transdermal administration due to their biocompatibility and biodegradability. Their lipophilicity and/or similarity to the natural lipids of the epidermis enable intermolecular interactions with the lipid membrane and therefore result in effective passage through the skin. The purpose of this review is to focus on lipid-based drug delivery nanoplatforms administered via the transdermal route by summarizing the most recent developments with the intention of fast clinical translation. Liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), ethosomes, and transfersomes exhibit ideal physicochemical characteristics and encapsulation efficiency to enhance the effectiveness of the incorporated Active Pharmaceutical Ingredients (APIs). The state of the art for fabricating transcutaneous lipid drug delivery nanoparticles and the strategies for overcoming the current obstacles, as well as the added value of novel formulations, will be discussed within the scope of Quality by Design applications. The limitations and challenges that still exist will also be considered.

5 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LALefkothea Antonara
Lefkothea Antonara
DRDimitrios Rekkas
Dimitrios Rekkas
Natassa PippaNatassa Pippa
Natassa Pippa
PDParaskevas P Dallas
Paraskevas P Dallas
Background/Objectives: Polymeric microneedles are an innovative drug delivery form combining the benefits of both transdermal and intravenous administration. However, their practical application is limited by fabrication challenges. To address this, the study explores a novel approach for the rapid, precise, and customized production of polymeric microneedles of diverse geometries by utilizing Liquid Crystal Display (LCD) 3D printing technology, marking the first reported use of this technique for microneedle mold fabrication. Methods: LCD 3D printing technology was applied to prepare resin biocompatible microneedle molds. The method developed was optimized by identifying and controlling the critical process parameters (CPPs) through implementing statistical experimental design techniques within the Quality by Design regulatory framework for pharmaceutical development. The optimized molds were subsequently utilized to produce polyvinyl alcohol microneedles with customized shapes and geometries. Representative designs were then loaded with Ropinirole Hydrochloride as a model drug and evaluated in relation to their morphology, drug content, skin insertion depth, and permeability. Results: The application of a Central Composite Design identified layer height and exposure time as the critical process parameters affecting mold fabrication. The optimized design space enabled the selection of printing conditions that maximized dimensional accuracy. Employing these optimum LCD 3D printing parameters, microneedles of various shapes and dimensions were successfully fabricated, exhibiting highly dimensional accuracy. Additionally, tuning skin permeability was proven to be feasible by adjusting microneedle geometry. Conclusions: This work demonstrates the successful use of LCD 3D printing technology in producing biocompatible molds for customized microneedle fabrication, facilitating the development of transdermal delivery systems with personalized drug permeation profiles.